>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: INTX -15.9%, GALE -15%, DNDN -14.2%, ATHX -12.1%, GCAP -9.8%, CALL -9.7%, MM -9.5%, BDE -8.6%, NUAN -7.7%, ALTV -6.9%, CXDC -6.6%, FLO -5.7%, CBPX -5.6%, WILC -5.4%, FST -5%, CZR -4.8%, GERN -4.7%, GNVC -3.7%, MTZ -3.6%, INO -3.3%, APP -2.2%, REN -1.5%, AEY -1.3%, CYNI -1.1%, .

Select oil/gas related names showing early weakness: TOT -1.3%, RDS.A -1.2%, BP -0.5%.

Other news: EPZM -41.4% (still checking, presenting at conf today), TKMR -7.4% (following 15% move higher), HCLP -5.1% (announced the commencement of an underwritten secondary public offering of 3,260,870 common units representing limited partner interests in the Partnership by Hi-Crush Proppants LLC), TCAP -3.9% ( announces commencement of public offering of 4 mln shares of common stock), SFM -3.7% (announces commencement of public offering of 15 mln shares of its common stock by affiliates of Apollo Global Management (APO) and certain other stockholders of the co), BPL -3.3% ( to offer 2.6 mln limited partnership units ), RSH -3.1% (mentioned cautiously at UBS-- thinks turn around efforts have been hampered), INSM -2.9% (commenced an underwritten public offering of $80 million of its common stock. All of the shares of common stock in the offering are to be sold by Insmed), RXN -2.9% (announced the launch of a public offering of 10,000,000 shares of its common stock held by certain funds affiliated with Apollo Global Management, LLC), INSM -2.9% (announced that it has commenced an underwritten public offering of $80 million of its common stock. All of the shares of common stock in the offering are to be sold by Insmed), MILL -2.7% (announces resignation of President David Voyticky), CMCM -1.8% (enters into share purchase agreement with a subsidiary of Tencent (TCEHY) to acquire an additional ~ 22.2% equity interest in Moxiu Technology (Beijing) for total consideration of RMB30 mln in cash), HTZ-1.6% (discloses that it will be unable to file its (June) Quarterly Report within the five day extension provided by Rule 12b-25(b)), REN -1.5% (still checking), LOCO -1.3% (negative mention on Mad Money), MNKD -1.2% (pulling back following yesterday's gain), DNOW -0.9% (following late insider buy disclosure -- CEO disclosed purchase of 7,900 shares at $30.74 worth $242,846 ).

Analyst comments: WHX -5.8% (downgraded to Underperform at Raymond James), TCK -2.7% (downgraded to Sell from Neutral at Goldman), CSX -0.7% (downgraded to Neutral from Outperform at Macquarie), SWN -0.7% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts)
.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: APRI +19.3%, SUPN +17%, SUPN +17%, INSY +15.8%, ERB +12.2%, DTSI +11.1%, TRAK +9.9%, CUI +9%, KATE +8.7%, STRI +6.8%, (also announces strategic relationship with the Zhenfa Energy Group), UCP +5.3%, SOL +4.6%, AER +4.2%, BTX +4.2%, NOAH +3.6%, UNTD +2.9%, ICUI +2.8%, ONTY +2.6%, PUK +2.2%, VAL+2.1%, MR +1.8%, FXEN +1.8%, ARRY +1.7%, ONVO +1.7%, TRVN +1.3%, TRQ +0.9%, GNMK +0.8%, HALO +0.7%, .

M&A news: FRF +40% (to be acquired by Tiptree Financial (TIPT) for $10.00 per share).

Select financial related names showing strength: BCS +1.4%, ING +0.9%, DB +0.5%.

Other news: ICPT +48.8% (discloses results from FLINT trial of obeticholic acid in nonalcoholic steatohepatitis), APRI +19.3% (enters into common stock purchase agreement with Aspire Capital), CNAT +10.7% (ICPT sympathy), STRI +6.8% (announces strategic relationship with the Zhenfa Energy Group), EXAS +5.7% (announces the FDA has approved Cologuard, the co's noninvasive, stool DNA colorectal cancer screening test), SMG +5.4% (declared special one-time cash dividend of $2/share; approves new share repurchase authorization of $500 mln; increases quarterly dividend to $0.45/share), SSNI +4.3% ( initiated with a Outperform at Northland Capital), BWP +3.5% (positive mention on Mad Money), CEMP +3.1% (announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.), ONTY +2.6% (announced acquisition of Alpine Biosciences for ~ 9.3 mln shares of common stock ($27 mln value)), ATLS +2.3% (positive mention on Mad Money), CNSL +2.2% (to replace TAYC in the S&P SmallCap 600), CIE +2.1% (Paulson & Co discloses 10.1% passive stake in 13G filing), TSL +1.9% (to develop 49.9MW solar power plant in UK), ETE +1.4% (positive mention on Mad Money), CSIQ +1.3% (modules to power 44 MW North Carolina solar farms), OPK +1% (announced Rayaldee Phase 3 trial met primary endpoints; top-line data from second identical pivotal Phase 3 trial expected in Sep 2014; NDA submission to the FDA on track for end of 2014).

Analyst comments: SKUL +6.1% (upgraded to Hold from Underperform at Jefferies), NBG +4.3% (upgraded to Buy from Neutral at Citigroup), SUNE +2.4% (reinstated with a Buy at Goldman), BC +2.1% (upgraded to Strong Buy from Mkt Perform at Raymond James), DF +2% (upgraded to Outperform from Neutral at Credit Suisse), ANF +1.9% (upgraded to Buy from Hold at Stifel), FSLR+1.5% (added to Focus List at Citigroup), KSU +0.6% (upgraded to Neutral from Underperform at Macquarie
)

>>> Apple Reportedly holding discussions with Mount Sinai, Cleveland Clinic, Joh

Apple Reportedly holding discussions with Mount Sinai, Cleveland Clinic, Johns Hopkins and Allscripts about implementing its new HealthKit services - press 
- Apple has shared few specific details on HealthKit, which will likely be included with the new iPhone 6 in September. Apple intends HealthKit to become part of a broader push into mobile healthcare. 
- Kaiser Permanente is currently testing mobile apps that make use of HealthKit

>>> US Early premarket gappers

Early premarket gappers
Gapping up: EXAS +13.5%, TRAK +13.3%, DTSI +11.8%, SUPN +10.3%, CUI +9%, CNAT +8.2%, RTRX +6.3%, SMG +5.3%, UCP +5.3%, INSY+5%, NBG +3.9%, SOL +3.9%, OPK +3.2%, CEMP +3.1%, UNTD +2.9%, ICUI +2.8%, CYNI +2.7%, ONTY +2.6%, ONTY +2.6%, CIE +2.5%,NOAH +2.4%, PUK +2.4%, AER +2.3%, CNSL +2.2%, HALO +2%, MR +1.8%, ARRY +1.7%, BCS +1.2%, P +1.1%, CCL +1%, ING +0.9%, TRQ+0.9%, GNMK +0.8%

Gapping down: GALE -16%, INTX -15.9%, NUAN -10.8%, CALL -10.7%, GCAP -9.8%, FLO -8.8%, MM -7.8%, CBPX -5.6%, FST -5%, CZR-4.8%, HCLP -4.7%, SFM -3.7%, TCAP -3.6%, MTZ -3.6%, GERN -3.1%, BPL -3%, INSM -2.9%, INSM -2.9%, APP -2.2%, TKMR -2.1%, DNDN-1.9%, ATHX -1.8%, RXN -1.5%, RAX -1.5%, REN -1.5%, TOT -1.4%, RDS.A -1%

(BFW) Ophir Falls; Lacks High Impact Drilling Program, SocGen Says

Ophir Falls; Lacks High Impact Drilling Program, SocGen Says
2014-08-12 08:39:47.392 GMT


By James Cone
Aug. 12 (Bloomberg) -- Ophir falls as much as 3.2% in 5th
day of declines as Societe Generale cuts to hold from buy,
reduces PT 34% to 230p, according to note.
* 2nd biggest decliner on SXEP oil & gas index, volume on shrs
~17% of 3-month daily avg
* SocGen: visible forward drilling program lack exposure to
high impact frontier exploration wells; sees shrs to be
influenced more by value of core assets rather than risked
upside over next 12 months
* Says potential upside from monetization solution of
Equatorial Guinea gas discoveries, remains contingent
asset as process to find FLNG partner seen likely in
2015
* At 1H results on Aug. 14, expects capex above forecast
($635m vs $500m) on increased expenditure in Gabon,
Myanmar, Seychelles
* Expects questions on potential of share buyback, sees
cash position at end 2014 ~$1b
* Ophir is down 39% YTD, 3rd biggest drop in SXEP (+3.1%)


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
James Cone in London at +44-20-7673-2572 or
jcone@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net